Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Erbitux Prescribers (US)(?)

Council Members in this Study Group: 60

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Michael Grossbard, MD
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

Haitham Al-Okk, MD, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer CenterHaitham Al-Okk, MD
Assistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center

Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Government Intervention is Here: Pharma had better get use to it.... | 10-06-2008
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: GLG Expert Contributor

"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.

Radon & Lung cancer: Outside of Uranium Mines is it Relevant??? | 10-03-2008
Analysis of: Protecting a Home From Silent Threat | www.nytimes.com
Author: GLG Expert Contributor

Radon is responsible for about 15% on lung cancer deaths in the US??

Idera Pharma: is there room for another agent in recurrent renal cell ca?? | 10-02-2008
Author: GLG Expert Contributor

Apparently Merck has an interest in this compound and it is in trial in combination in other neoplasms.

Epo & Stroke: The chickens coming home to roost. | 09-30-2008
Analysis of: F.D.A. Reviewing Deaths in Anemia Drug Study | www.nytimes.com
Author: GLG Expert Contributor

Epo (J & J's version) increased mortality when given to patients with a new stroke in an effort to improve brain function. What will this lead too?? 

Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it? | 09-29-2008
Analysis of: Medicare Drug Premium on Rise | online.wsj.com
Author: GLG Expert Contributor

Costs for Medicare part D are going up 31%

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Partner
  • Owner
  • Physician - Director
  • President
  • Consultant

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-10-07T13:45:18.680